Alimentary Pharmacology and Therapeutics
Издатель: Wiley · ISSN 02692813 · 89 статей
- Long‐Term Real‐World Switch Rates and Adherence Among Patients With Ulcerative Colitis Treated With Upadacitinib or Tumour Necrosis Factor Inhibitors
- Letter: Does Faecal Calprotectin Meaningfully Change Biopsy Decisions in Microscopic Colitis?
-
Efficacy and Predictors of Response to a Low‐FODMAP Diet in Patients With Overlap of Functional Dyspepsia and Irritable Bowel Syndrome: A Prospective Multicentre Randomized Clinical Trial
ABSTRACT Background and Aims Functional dyspepsia (FD) frequently coexists with irritable bowel syndrome (IBS), resulting in a complex clinical phenotype characterized by prominent postprandial symptoms and limited treatment options. We...
- Letter: From qHBsAg Correlation to Clinical Stratification—What Evidence Is Still Needed for Rapid HBsAg Time to Positivity?
- Letter: Discrepant Case Ascertainment and Misclassified ESRD Definition in an IBD Cohort—35% Unaccounted Dialysis Cases
- Letter: P‐CABs Versus PPIs for Gastroprotection During Antithrombotic Therapy: What Does Treatment Switching Tell Us?
- Letter: Clarifying the Interpretation of Dialysis Risk in Inflammatory Bowel Disease
- Letter: Methodological and Contextual Considerations for Time to Positivity of a Rapid HBsAg Assay. Authors' Reply
- Letter: From qHBsAg Correlation to Clinical Stratification—What Evidence Is Still Needed for Rapid HBsAg Time to Positivity? Authors' Reply
- Letter: Acute Severe Ulcerative Colitis in the Advanced Therapy Era: Is Lowering the CRP Threshold Enough? Authors' Reply
- Letter: Clarifying the Interpretation of Dialysis Risk in Inflammatory Bowel Disease. Authors' Reply
- Letter: Discrepant Case Ascertainment and Misclassified ESRD Definition in an IBD Cohort—35% Unaccounted Dialysis Cases. Authors' Reply
- Review Article: Cancer Surveillance for Early Detection of Liver Cancer in Patients with HBV Infection
- Correction to “Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents”
- Editorial: Taking a Different Route–Navigating the Switch From Intravenous to Subcutaneous Vedolizumab
- Editorial: Host Innate Immunity Reaches the Clinic—The Laboratory of Genetics and Physiology Protein 2 (LGP2) Q425R Variant and Severity of Chronic Hepatitis Delta
- Editorial: The Next Frontier in Alcohol‐Associated Liver Disease: Integrating Social Determinants of Health Into Risk Stratification and Care Delivery
- Editorial: How Can We Best Detect Frailty in Older Patients With Inflammatory Bowel Disease?
- Editorial: How Can We Best Detect Frailty in Older Patients With Inflammatory Bowel Disease? Authors'Reply
- Editorial: The Next Frontier in Alcohol‐Associated Liver Disease—Integrating Social Determinants of Health Into Risk Stratification and Care Delivery. Authors' Reply
- Letter: Moving Beyond Intragastric pH in Linaprazan Glurate Development
- Letter: Interpreting HBV Reactivation Incidence–Cohort Selection, Competing Risks and Corticosteroid Exposure
-
Review Article: Cirrhosis Recompensation‐ Definition, Natural History, Clinical Implications and Considerations for Clinical Trials
ABSTRACT Background and Aims Decompensated cirrhosis has traditionally been considered irreversible. However, evidence shows that patients who achieve control or cure of the underlying liver disease aetiology can experience substantial...
- Letter: Colorectal Cancer Risk After Faecal Immunochemical Testing—Which Risk Should Guide Referral? Authors' Reply
- Editorial: Objective Follow Up of Inflammation After Therapy for Eosinophilic Oesophagitis. Authors' Reply
- Letter: Advanced Therapies for PSC‐IBD: A Persistent Scarcity of Data
- Letter: More Than the Sum of Its Parts—What Does ALBI Add to Interleukin‐6?
-
Carbon Footprint of Diagnostic Modalities Used in Inflammatory Bowel Disease Care: The EVERGREEN‐IBD Study (EVERGREEN‐IBD: Evaluating Value, Emissions, Resource Use, and GREEN diagnostics in IBD)
ABSTRACT Background Healthcare contributes 4.4%–5% of global greenhouse gas emissions. Inflammatory bowel disease (IBD) requires repeated diagnostic investigations throughout a patient's lifetime, adding to healthcare's environmental...
- Editorial: Not All Fibres Are Created Equal—Fibre Supplements for Personalised Application. Authors' Reply
- Letter: Anticoagulation After Gastrointestinal Bleeding—Prognostic Associations are not Treatment Effects